Electromed (ELMD) Q1 2025 earnings summary

Executive summary

• Achieved eighth consecutive quarter of year-over-year revenue and profit growth, with net revenue of $14.7 million, up 19% year-over-year, driven by strong homecare and hospital sales.

• Net income rose to $1.5 million ($0.16 per diluted share) from $0.2 million ($0.02 per diluted share) year-over-year, reflecting improved gross margin and higher sales.

• Operating income reached $1.9 million, a significant increase from $0.1 million in the prior year, as revenue growth outpaced expense increases.

• Strategic focus on expanding sales team, direct-to-consumer investments, and manufacturing process improvements, including the launch of the "Triple Down on Bronchiectasis" campaign.

• Repurchased 262,756 shares for $4.54 million, nearing the $5 million authorization.

Financial highlights

• Net revenue grew 19% year-over-year to $14.7 million; homecare revenue rose 18.5% to $13.2 million; hospital revenue increased 36.1% to $690,000.

• Gross profit was $11.5 million (78.3% of net revenues), up from $9.5 million (77.1%) in the prior year.

• Operating income was $1.9 million (13.2% of revenue), up from $0.1 million (1.2%) last year.

• SG&A expenses increased 2.6% to $9.4 million, mainly due to higher compensation and share-based awards.

• R&D expenses decreased 19.4% to $166,000 as product development costs declined.

Outlook and guidance

• Management expects to deliver double-digit top-line growth and expanded operating leverage for the full year, with sufficient working capital and liquidity.

• Continued focus on sales force expansion, direct-to-consumer efforts, and payer relations to drive future growth.

• Macroeconomic factors such as inflation are being monitored, but liquidity is expected to remain adequate.